JNCCN 360 - BiomarkerNTRK - Available Clinical Trials

Editors:

Alexander Drilon, MD

Gregory J. Riely, MD, PhD

Advertisement

Advertisement

Available Clinical Trials

A Study of Alectinib, Entrectinib, Vemurafenib Plus Cobimetinib, or Pralsetinib in Patients With Resectable Stages II-III Non-Small Cell Lung Cancer With ALK, ROS1, NTRK, BRAF V600, or RET Molecular Alterations

A Study of Repotrectinib in Pediatric and Young Adult Patients Harboring <em>ALK, ROS1,</em> or <em>NTRK1–3</em> Alterations

A Study to Test the Effect of Larotrectinib in Adults and Children With <em>NTRK</em> Fusion–Positive Solid Tumors (NAVIGATE)

A Study to Test the Safety and Efficacy of Larotrectinib in Treatment of Tumors With <em>NTRK</em> Fusion in Children (SCOUT)

A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults

Basket Study of Entrectinib (RXDX-101) in the Treatment of Patients With Solid Tumors Harboring em>NTRK1/2/3</em> (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)

Larotrectinib in Treating Patients With Previously Untreated <em>TRK</em> Fusion Solid Tumors and <em>TRK</em> Fusion Relapsed Acute Leukemia

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body (ON-TRK)

Sections

NCCN Resources

Copyright © 2022 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.